Article Text

PDF
SAT0494 Long-Term Retention and Predictors of Anti-Tnf Treatment Response in Juvenile Idiopathic Arthritis: Data from Reuma.PT, a Nation-Wide Register
  1. A.F. Mourão1,
  2. M.J. Santos2,
  3. J.A. Melo Gomes3,
  4. F. Martins4,
  5. S. Mendonça4,
  6. F.O. Ramos5,
  7. S. Fernandes6,
  8. M. Salgado7,
  9. M. Guedes8,
  10. S. Carvalho9,
  11. J.A. Costa10,
  12. I. Brito11,
  13. C. Duarte12,
  14. C. Furtado13,
  15. G. Sequeira14,
  16. A. Lopes15,
  17. A. Rodrigues15,
  18. J.C. Branco16,
  19. J.E. Fonseca17,
  20. H. Canhão18
  1. 1Rheumatology, Rheumatology Research Unit, Instituto de Medicina Molecular and Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental and CEDOC, Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon
  2. 2Rheumatology, Rheumatology Research Unit, Instituto de Medicina Molecular, Rheumatology Department, Hospital Garcia de Orta, Almada
  3. 3Instituto Português de Reumatologia, Lisbon
  4. 4Rheumatology, Portuguese Society Of Rheumatology, Lisbon
  5. 5Rheumatology, Rheumatology Department, Lisbon Academic Medical Center, Lisbon
  6. 6Rheumatology, Instituto Português de Reumatologia, Lisbon, Lisbon
  7. 7Pediatrics, Centro Universitário Hospitalar de Coimbra (CHUC) Coimbra, Coimbra
  8. 8Pediatrics, Unidade de Imunologia Clínica, Centro Hospitalar do Porto, Porto, Porto
  9. 9Pediatrics, Centro Hospitalar do Médio-Ave, Famalicão, Famalicão
  10. 10Rheumatology, ULSAM – Hospital Conde de Bertiandos, Ponte de Lima, Viana do Castelo
  11. 11Rheumatology, Rheumatology Department, Hospital de São João, Porto and Faculdade de Medicina da Universidade do Porto, Porto, Porto
  12. 12Rheumatology, Centro Universitário Hospitalar de Coimbra (CHUC) Coimbra, Coimbra
  13. 13Rheumatology, Hospital do Divino Espírito Santo, S. Miguel, Açores, Ponta Delgada
  14. 14Rheumatology, Rheumatology Department, Centro Hospitalar do Algarve, Faro., Faro
  15. 15Rheumatology, Rheumatology Research Unit, Instituto de Medicina Molecular
  16. 16Rheumatology, CEDOC, Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon and Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon
  17. 17Rheumatology, Rheumatology Research Unit, Instituto de Medicina Molecular andLisbon Academic Medical Center, Lisbon
  18. 18Rheumatology, Rheumatology Research Unit, Instituto de Medicina Molecular and Lisbon Academic Medical Center, Lisbon, Lisbon, Portugal

Abstract

Objectives To assess the effectiveness and safety of biological therapy as well as predictors of response after 1 year of therapy, the retention rate in biological treatment and predictors of drug discontinuation in JIA patients registered in the Portuguese register of rheumatic diseases, Reuma.pt.

Methods We collected prospectively patient and disease characteristics from patients with JIA who started biological disease modifying antirheumatic drugs. Adverse events were collected during the overall follow-up period. The predictors of response at 1 year were assessed and drug retention rates were calculated at 4 years of treatment for the first biologic agent using the Kaplan-Meier method.

Results Of the 812 JIA patients registered in Reuma.pt, 227 received biological therapy. The mean age at disease onset was 7.5±4.9 years and the mean age at the beginning of biological therapy was 16.2±9.4 years. The most common JIA category on biologics was polyarticular rheumatoid factor (RF) negative (23.3%). Most patients (90.3%) were treated with an anti-TNF as first biologic (etanercept, 69.2%). Disease activity decreased significantly at 6 months and 1 year of treatment. Fourteen patients discontinued biological therapies during the follow-up period due to adverse events. Baseline JADAS10 was the strongest predictor of treatment response at 1 year of biological therapy, with a 0.73 decrease for each unit increase at baseline (95% CI 0.45-1.10, p<0.001). Retention rates for the first biological agent were: 92.9% at 1 year, 85.5% at 2 years, 78.4% at 3 years and 68.1% at 4 years of treatment. Among all JIA subtypes, only concomitant therapy with corticosteroids was found to be univariately associated with withdrawal of biological treatment (p=0.016).

Conclusions Data from Reuma.pt confirm that biological therapies are effective and safe in patients with JIA. Additionally, baseline disease activity was the strongest predictor of treatment response and the retention rates for the first biological agent are high throughout 4 years.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.